Results 101 to 110 of about 25,328 (173)

Real-world survival benefit of adding durvalumab to chemotherapy in cholangiocarcinoma: a retrospective cohort analysis from a German Comprehensive Cancer Centre. [PDF]

ESMO Real World Data Digit Oncol
Elbasan S, Kasper S, Mavroeidi IA, Kostbade K, Siveke J, Spelsberg L, Majorczyk S, Neuhaus A, Akbari S, Wiesweg M, Baba H, Hartmann S, Schmidt H, Neumann U, Albers D, Markus P, Schuler M, Virchow I.   +17 more
europepmc   +1 more source

Utilizing Machine Learning to Identify Multimodal Signatures for Patients Who Would Benefit from the Addition of Tremelimumab to Durvalumab and Chemotherapy (TRIDENT). [PDF]

Clin Cancer Res
Skoulidis F, Jabbour SK, Garon EB, Iyengar P, Scagliotti G, Ferrer L, Etchepare G, Gallinato O, Faure J, Bernard P, Colin T, Menu P, Lin Y, Cai L, Chaudhry AA, Remorino A, Stewart R, Luciani-Silverman L, Miller K, Dellamonica D, Faria J, Zhang Y.   +21 more
europepmc   +1 more source

Visualizing the distribution of durvalumab targeting PD-L1 using quantitative fluorescence imaging in patients with esophageal cancer. [PDF]

Theranostics
van der Waaij AM, van Ginkel YJ, Volkmer P, Kats-Ugurlu G, Huizinga HK, Hone Lopez S, de Haan JJ, Bijlsma R, van der Waaij LA, Muijs CT, Niezink AGH, van Etten B, Westerhof J, di Pietro M, Robinson DJ, Lub-de Hooge MN, Nagengast WB.   +16 more
europepmc   +1 more source

Durvalumab-associated nephrotic syndrome and organizing pneumonia: a case report. [PDF]

CEN Case Rep
Nawata T, Shibuya M, Asami-Noyama M, Uesugi N, Sano M.   +4 more
europepmc   +1 more source

Sequential Immune Activation of Effector T Cells as Biomarkers of Response to Durvalumab in Patients with Locally Advanced NSCLC. [PDF]

Clin Cancer Res
Mouri A, Kenmotsu H, Kagamu H, Azuma K, Saito R, Akamatsu H, Yonesaka K, Kakegawa M, Nagashima H, Takahashi S, Fujita M, Yanagitani N, Ninomiya K, Nishioka Y, Mori K, Kitano S, Tamada K, Yamamoto N, Gemma A, Mitsudomi T.   +19 more
europepmc   +1 more source

Publisher Correction: Ceralasertib Plus Durvalumab in Chinese Patients with Advanced Solid Tumors: A Nonrandomized Clinical Trial. [PDF]

Oncol Ther
Sun Y, Zhong J, Sun H, Parr G, Lukacs E, Slade D, Zhou Y, Ren X, Kirk D, Kmieciak A, Yao T, Wang J.   +11 more
europepmc   +1 more source

Safety and Biomarker Analysis of NRG-LU004: Phase I Trial of Accelerated or Conventionally Fractionated Radiation Therapy Combined With Durvalumab in Programmed Death Ligand-1-High Locally Advanced Non-small Cell Lung Cancer. [PDF]

Int J Radiat Oncol Biol Phys
Lin SH, Pugh SL, Valle DMD, Roudko V, Edelman MJ, Doemer AJ, Simone CB, Nie K, Rizakos T, Mugunthan A, Zhang R, Kelly G, Beckmann N, Thompson RC, Kim-Schulze S, Gonzalez-Kozlova E, Gandhi S, Bikkina S, Karim N, Shen X, Badiyan SN, Higgins KA, Chakravarti A, Werner-Wasik M, Schallenkamp JM, Suarez-Farinas M, Gnjatic S, Tsao AS, Bradley JD.   +28 more
europepmc   +1 more source

Pathological Complete Response after Conversion Surgery for Distal Cholangiocarcinoma with High Tumor Mutational Burden and Para-Aortic Lymph Node Metastasis: A Case Report. [PDF]

Surg Case Rep
Hatano K, Okamura Y, Nakao K, Tanke G, Yamamoto G, Uryuhara K, Narita M, Hara S, Kaihara S.   +8 more
europepmc   +1 more source

InDuRanS: neoadjuvant immunochemotherapy followed by surgery or definitive chemoradiotherapy and consolidation durvalumab in resectable and borderline resectable stage IIB-IIIA/B non-small-cell lung cancer. [PDF]

Front Oncol
Gkika E, Waller CF, Dejonckheere CS, Layer JP, Meiners J, Brossart P, Rodermann E, Schiefer AS, Münter M, Nicolay NH, Grosu AL, Rimner A, Schmidt J, Schmid S.   +13 more
europepmc   +1 more source

Innovative Strategies in the Treatment of Unresectable Locally Advanced NSCLC: A Focus on Radiation Therapy. [PDF]

Cancers (Basel)
Galaverni M, Cerrato M, Giaj-Levra N, Ciammella P, Arcidiacono F, Anselmo P, Colombo F, Dionisi V, Montesi G, Borghetti P, Bruni A, Tiseo M, D'Abbiero N, Ricardi U, Simoni N.   +14 more
europepmc   +1 more source